1. Dupilumab improves sleep quality in chronic rhinosinusitis with nasal polyps.
- Author
-
Riva G, Garetto M, Borgione M, Piazza F, Prizio C, Dellea D, Albera A, Canale A, and Pecorari G
- Subjects
- Humans, Male, Female, Chronic Disease, Middle Aged, Retrospective Studies, Adult, Treatment Outcome, Quality of Life, Aged, Rhinosinusitis, Nasal Polyps complications, Nasal Polyps drug therapy, Sinusitis drug therapy, Sinusitis complications, Rhinitis drug therapy, Rhinitis complications, Antibodies, Monoclonal, Humanized therapeutic use, Sleep Quality
- Abstract
Purpose: Chronic rhinosinusitis with nasal polyps (CRSwNP) often alters sleep quality. Dupilumab emerged as an innovative and effective therapy for refractory/recurrent severe CRSwNP. The aim of this observational retrospective study was to evaluate the sleep quality in patients with CRSwNP who underwent treatment with dupilumab., Materials and Methods: Forty-five patients treated with dupilumab for CRSwNP were enrolled. Clinical parameters (age, sex, comorbidities, Nasal Polyp Score - NPS, Asthma Control Test - ACT), nasal cytology, quality of life (Sino Nasal Outcome Test 22 - SNOT-22), sleep quality (Pittsburgh Sleep Quality Index - PSQI, Epworth Sleepiness Scale - ESS), and risk of sleep apnea (STOP-BANG) were recorded before treatment (T0), and after 3 (T1), 6 (T2), and 12 months (T3)., Results: NPS, ACT and SNOT-22 total score improved during treatment (p < 0.05). Meanwhile, all sleep parameters evaluated with SNOT-22, ESS and PSQI improved over time (p < 0.001), expect for PSQI Use of sleeping medications. Indeed, sleep drugs are rarely used before and during the treatment. The global sleep quality was classified as poor in 88.9 % of cases at T0 and decreased to 5.7 % at T3. A high risk of sleep apnea was revealed by the STOP-BANG in 68.9 % of cases at T0 and 2.8 % of patient at T3 (p < 0.001)., Conclusions: Dupilumab improves the sleep quality and reduce the risk of sleep apnea in patients with severe CRSwNP. Its favorable effect occurs within 3 months and is maintained during the treatment., Competing Interests: Declaration of competing interest None., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF